Biotech pharma

Nephrogen

Website

Nephrogen is a Stanford biotech spin-out developing curative genetic medicines for kidney and pancreatic diseases. Kidney disease alone affects 1 in 7 Americans, and neither indication has any approved gene-based therapies. Nephrogen's underlying platform combines AI and high-throughput screening to engineer safer, more efficient, and less expe

Founded 2022Origin source ↗Checked 2026-09-15

Overview

Nephrogen is a Stanford biotech spin-out developing curative genetic medicines for kidney and pancreatic diseases. Kidney disease alone affects 1 in 7 Americans, and neither indication has any approved gene-based therapies.

Nephrogen's underlying platform combines AI and high-throughput screening to engineer safer, more efficient, and less expensive gene delivery vehicles for reaching the kidney and pancreas, and has attracted non-dilutive funding from seven major pharmaceutical companies including Merck KGaA, Novartis, and Bristol Myers Squibb.

Company description As recorded 2026-11-08

Founders & team

No directly sourced team information is available yet.

5team members reported
Source-reported As recorded 2026-09-15

Founded 2022 · Source

News & product activity

Sources & observations

Y Combinator

Profile depthverified profile
Website observationwebsite reachable
Last website check2026-11-11
Location · source statedNew York City, NY, USA
Pricing evidenceNo pricing page confirmed
Maturity: Not assessed · 2 of 6 areas documented

Source-based assessment · automated evidence rules

The retained text does not establish product availability or customer use.

Maturity is an evidence-based assessment, not a success rating. It may understate the current stage where evidence is limited. Coverage records documented areas, not a complete or independently audited company history.

Stage definitions
independent websitesource corroborationreachable websitedescriptive evidenceclassified market and modelsourced founding year